Latest news

RCD | | David Pintos Widmer
ARTHEx raises its funding round to USD 87 million for the development of its programme for myotonic dystrophy type 1, a rare genetic neuromuscular disease
RCD news

ARTHEx Biotech, a clinical-stage biotechnology company focused on the development of RNA therapeutics targeting rare genetic neuromuscular disorders, has closed its funding round with the addition of a new investor, Bpifrance, and the participation of all existing shareholders, bringing the total amount to USD 87 million

RCD names five new partners through internal promotion
RCD news

The firm reaffirms its commitment to talent and legal excellence by promoting individuals with extensive experience within the firm